Navigation Links
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

er and lung cancer as well as a Phase 3 study, to be initiated shortly, in adjuvant melanoma.

For further information about ipilimumab clinical trials, please visit http://www.clinicaltrials.gov.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to the development of ipilimumab may constitute forward- looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, such as statements preceded by, followed by or including the words
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
6. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
10. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015  When Ryan Rendino ... side of his neck, he figured it ... couple weeks off from weight lifting. ...                               A series of ... referred to Michel Kliot, MD , ...
(Date:5/21/2015)... , May 21, 2015  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... quarterly cash dividend for the second quarter 2015 of ... cash dividend of $0.03 per share will be paid ... record as of June 12, 2015.  The ex-dividend date ...
(Date:5/21/2015)... 21. Mai 2015 Dipexium ... ein Unternehmen für Arzneimittel im fortgeschrittenen ... und Vermarktung von Locilex® (Pexiganan-Creme 0,8 %) ... eine wissenschaftliche Posterpräsentation an, welche das ... vorstellt, OneStep-1 und OneStep-2, in der ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... , ALBUQUERQUE, N.M. , ... molecular diagnostics laboratory that discovers, develops and markets proprietary ... agreement with EndoChoice, Inc. to promote its diagnostic services ... Under the agreement, EndoChoice,s experienced, gastroenterology-focused sales force will ...
... , DULUTH, Ga. , Feb. 16 ... from the U.S. Department of Agriculture for ONCEPT™ Canine Melanoma ... in extending survival of dogs with stage II or stage ... cancer in dogs. , ONCEPT is the first and ...
Cached Medicine Technology:Exagen Diagnostics Enters Into Exclusive Agreement With EndoChoice 2MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine 2MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine 3MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine 4MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine 5
(Date:5/24/2015)... 2015 The federal court overseeing ... has scheduled its next monthly Case Management Conference ... According to court documents filed in the U.S. ... will be convened on June 2, 2015, at ... Liability Litigation - MDL No. 2545) , “Our ...
(Date:5/24/2015)... 24, 2015 ... - The students were selected ... the fourth annual A Day of ... Geneva National in Lake Geneva. , ... High School,         Jonathan Alfonso,         Bridget Keefe, ...
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
(Date:5/23/2015)... AZ (PRWEB) May 23, 2015 Manufacturers are ... Seasonal Performance Factor (HSPF) of 8.2. Experts in the field ... ultimately benefit consumers. , The HSPF score is what miles ... the more efficient the unit. Although the minimum HSPF score ... water heaters with an HSPF score north of 12. Indeed, ...
(Date:5/23/2015)... 2015 Injury lawyer Steven H. Heisler commented ... by the Maryland legislature but which has not been signed ... passed HB 449 with overwhelming bipartisan support on ... it into law. This bill ensures that fracking is prohibited ... demonstrates the danger of fracking to our water supplies and ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3
... NYSE Agrees to a Trading Extension of KV,s Securities until February ... ... 2008, ST. LOUIS, Dec. 28 KV Pharmaceutical Company,(NYSE: ... markets technology differentiated,branded and generic/non-branded prescription pharmaceutical products,announced today that NYSE ...
... restricted calorie intake for diabetics wanting to manage their ... the first time, the American Diabetes Association (ADA) has ... with diabetes who want to manage their weight. , ... low-carbohydrate diets in its newly published 2008 clinical ...
... (NYSE: MYL ),today announced that Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New,Drug Application (ANDA) for ... Cetirizine HCl Tablets are the generic version of Pfizer,s ... for the 12,months ending Sept. 30, 2007., This ...
... December 28, 2007 In the United States, the ... Of the $1.9 billion in direct costs, glaucoma medications ... total. In an article published in the January 2008 ... The Texas A&M University System Health Science Center College ...
... an Interactive Arcade for Kids, Teens, and Adult Gamers ... largest 59,000,sq. ft. Mega-Center officially opened for workouts on ... Chester just off Cincinnati-Dayton,Road & I-75 next to Wal-Mart. ... which includes a silent auction on Saturday, January,19th from ...
... ATLANTA, Dec. 27 Eclipsys Corporation(R),(Nasdaq: ECLP ... be,participating in the 2008 JPMorgan Healthcare Conference taking ... CA., (Logo: http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), ... Tuesday, January,8th at 3:00 p.m. Pacific time. To ...
Cached Medicine News:Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News: Diabetes Group Backs Low-Carb Diets 2Health News:Cost of glaucoma medications may impact treatment 2Health News:Fitworks West Chester Mega-Center Now Open 2Health News:Fitworks West Chester Mega-Center Now Open 3Health News:Eclipsys to Present at JPMorgan Healthcare Conference 2Health News:Eclipsys to Present at JPMorgan Healthcare Conference 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: